Abstracts tagged "Publication"

Abstract Number: 327 • 2019 ACR/ARP Annual Meeting
Presentation Order Bias in Rheumatology Journals: A Content Analysis
Sarah Stewart¹, Greg Gamble ², Andrew Grey ² and Nicola Dalbeth ², ¹University of Auckland, Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand
Background/Purpose: Presentation order can influence the prominence of an academic article. Earlier-listed items or those at the top of tables of contents are more likely…
Abstract Number: 991 • 2017 ACR/ARHP Annual Meeting
Publication Timeliness of the Randomized Controlled Trials of Drug Therapy for Inflammatory Arthritis
Vyjayanthi Ganga¹, Mohan Edupuganti² and Nasim A. Khan³, ¹St. Vincent Healthcare System, Little Rock, AR, ²Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, ³Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR
Background/Purpose: Timely publication of randomized controlled trials (RCTs) is crucial for their potential impact on patient care. We assessed the publication timeliness of drug therapy…
Abstract Number: 264 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials
Tara Landry¹, Mary-Ann Fitzcharles², Peter A. Ste-Marie³ and Yoram Shir³, ¹Montreal General Hospital Medical Library, Mcgill University Health Centre, Montreal, QC, Canada, ²Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ³Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: The endocannabinoid system functions to maintain homeostasis in the human body and thereby has effects on modulation of pain and inflammation. Cannabinoid preparations are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].